SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10 - sprookjes - yvandenbroek - TriplyDB

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

http://www.wikidata.org/entity/Q24797335

about

Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth Role of Chemokines in Non-Small Cell Lung Cancer: Angiogenesis and Inflammation Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment CCL21 Chemokine Therapy for Lung Cancer.Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.Chemokines as mediators of tumor angiogenesis and neovascularization Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.CXC chemokines in cancer angiogenesis and metastases Chemokines as mediators of neovascularization Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection.CCL21 Cancer Immunotherapy.Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.A biotherapy based on PSCs-in-3D spheroid-ameliorated biologics depletes in vivo cancer-sustaining stem cells.Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy.The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector.Review paper: the role of inflammation in mouse pulmonary neoplasia.Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors.The role of CXC chemokines and their receptors in the progression and treatment of tumors.Chemokine-based immunotherapy: delivery systems and combination therapies.Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro.CXC and CC chemokines as angiogenic modulators in nonhaematological tumors.

P2860

Q21560837-63182ECC-003E-420D-BC7A-6DDDB87D02D6 Q26796395-9E90FEC7-D219-4B2B-814C-C7F05B0E53B9 Q26799123-61A8D344-6EC1-4ED4-9043-249BDC7B718E Q28248811-8F8552C4-5CB5-4B11-B009-CE249C1EFC4C Q30426606-00E032D7-60BF-4601-8F8D-4FBB01AA781A Q30427886-BEB70294-E00B-4C61-A768-220492C05541 Q30428793-B6413578-9C65-4A1A-A8EA-8E823CD358A2 Q30432791-DA798061-1C9A-4F55-85D8-CA346C40F339 Q30438032-F869541D-9ECB-4218-9D22-1BEC30E34CD5 Q33584637-E1FEEDD4-6930-4A0F-85C8-FA8D8E334E9B Q33803567-6E33EF87-0D4B-4FDF-A3C8-1F6D9FA80E1F Q33820300-62FE98F8-87FF-4A66-A3EF-BFC3FD291C68 Q33862487-60294CED-8929-4B4B-98CC-C1D5E855AEAF Q34205801-B548AB66-3E73-4CC5-9EF5-FE135C3C7829 Q35713347-C6D97067-88C6-4D84-AED2-F5277F170C10 Q35842700-4CDCE43A-301E-44A7-B784-5A8BF93C218E Q35947942-AAD9E6FA-BCB4-4890-8224-5E3C3861E0CA Q36562161-C51D5B55-1DBC-4B93-8C29-9F9B4EF672D6 Q37116507-0E262A84-F1E5-48E1-B02C-EC3D843BB9F5 Q37298417-DD2ECD9E-5921-40F0-8F48-F76B842F6024 Q37379547-A1B31AFE-6869-4CE1-AC44-A33B4E4725CC Q37900430-EAD0E8B0-B926-488C-81D8-48B6FBCFF53D Q38023245-C0216266-1693-45ED-AB1A-F388FC5ADABC Q38040509-CA1F226F-A758-49C1-BE9D-51B16052EF39 Q38688006-E4734ADF-303C-424E-B04B-B1BF846A841E Q39185087-956F2A3F-6755-4EBE-B843-3E26337727D2 Q39787154-54397466-A612-4D3B-9973-6CC27AECDCA9 Q40724369-00B39D40-8E17-43FD-A10D-313E9440D302

P2860

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

http://www.wikidata.org/entity/Q24797335

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@ast

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@en

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@nl

type

label

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@ast

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@en

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@nl

prefLabel

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@ast

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@en

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@nl

P1433

Q24797335-D1C4DB29-66B8-4523-BA11-7DF652A59F95

P1476

Q24797335-E859BA4C-A0EC-4266-A649-D50CBD009D97

P2093

Q24797335-14AC2B72-799E-4674-B555-F4010227116E

Q24797335-24EAFF36-FEFF-487E-BBBF-79467B41A770

Q24797335-4149AB1E-D00D-42D3-9DE2-EFA896BE2532

Q24797335-459D122C-6586-4F06-ACCA-60A5AFE4577B

Q24797335-4B14A105-C470-4C21-98A8-4AA3976902E2

Q24797335-533C6BEF-9111-422C-BEC9-2B87793D4071

Q24797335-5E4C960D-BF10-4844-B0BB-B7AE89CF8F3E

Q24797335-88297A20-AFC8-446C-8018-98FC9351C198

Q24797335-AFABADF6-5094-4893-BBB7-22186441A663

Q24797335-B0C242A6-4A45-481C-A951-55E0D81DFEE6

P2860

Q24797335-0710C543-BDD4-4062-812B-033443873444

Q24797335-0AB82F7A-CF6B-41B6-A48F-DF1822A072CC

Q24797335-15BEAC03-9251-4C80-8C37-AC229D0E7E73

Q24797335-1A5E0F0E-5047-4791-800F-D31F355E59A4

Q24797335-1AC40A93-3119-4685-B8EF-26E4DA9F4A43

Q24797335-1B7EA08C-EC2D-440A-A513-E37FB6F6BE4A

Q24797335-2C467BC4-12DA-41AC-880B-4445064014FD

Q24797335-30FBB122-9E4F-4336-90A6-8115EB54267D

Q24797335-311B8845-4412-4E6D-97DB-0CDF0F90C9DF

Q24797335-39A13DC7-0DEF-455D-89A7-B3522654895C

P2888

Q24797335-44ADA94F-9535-45DF-9DD9-31DC61A2DB64

P304

Q24797335-AA5007C9-A6CF-4CBE-9FD4-CE96C042747D

P31

Q24797335-56CC468D-9179-4A6C-9B1F-64B5C55269E1

P3181

Q24797335-ED99EEBA-AB00-47BD-B998-A9B9ED711721

P356

Q24797335-5EECDD95-2FA3-436B-82F1-E2B5E2A7446B

P407

Q24797335-D8EE6CE6-574B-44B3-9471-8CEE0E839339

P433

Q24797335-86DD351E-72B3-476E-A75A-CA6FE496EF0B

P478

Q24797335-31EAA462-73DC-4719-989E-DFC9419A661F

P577

Q24797335-3A88B761-E3C9-4636-8A04-E4A5A83BCF29

P5875

Q24797335-43165BDA-B520-4934-84AC-736E211DD421

P6179

Q24797335-E116F595-9E4F-4A41-8E96-F7DAE2CAC4A9

P698

Q24797335-53484681-06BF-48A3-AFBB-56D3D08D3906

P932

Q24797335-9C0067B9-13EE-4B3D-856A-A239F3D18017

P3181

P356

P1433

Molecular Cancer

P1476

SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10

@en

P2093

Jeff F Lin

http://www.w3.org/2001/XMLSchema#string

Li X Zhu

http://www.w3.org/2001/XMLSchema#string

Marie D Burdick

http://www.w3.org/2001/XMLSchema#string

Min Huang

http://www.w3.org/2001/XMLSchema#string

Raj K Batra

http://www.w3.org/2001/XMLSchema#string

Robert M Strieter

http://www.w3.org/2001/XMLSchema#string

Seok-Chul Yang

http://www.w3.org/2001/XMLSchema#string

Sherven Sharma

http://www.w3.org/2001/XMLSchema#string

Steven M Dubinett

http://www.w3.org/2001/XMLSchema#string

Sven Hillinger

http://www.w3.org/2001/XMLSchema#string

P2860

Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes

Human Mig chemokine: biochemical and functional characterization

Identification and characterization of a novel beta chemokine containing six conserved cysteines

Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension

Mig and IP-10: CXC chemokines that target lymphocytes

Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma

Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs

Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung.

P2888

P304

22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4705316

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1476-4598-2-22

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10766263

http://www.w3.org/2001/XMLSchema#string

P6179

1046503341

http://www.w3.org/2001/XMLSchema#string

P698

12740040

http://www.w3.org/2001/XMLSchema#string

P932

155639

http://www.w3.org/2001/XMLSchema#string